Intelligence Profile
Clinical Applications
Based on available evidence, IV exosome therapy is being investigated for several therapeutic applications, though clinical data remains limited and primarily at the preclinical stage.
Neurological Conditions
The strongest preclinical evidence exists for neurological applications. Research shows that exosomes derived from mesenchymal stem cells may help treat intracerebral hemorrhage by reducing neuroinflammation through modulation of lactylation modifications and the SIRT6/Notch1/NF-κB signaling pathway. These findings suggest potential for treating brain injury and stroke-related complications.
Early-stage clinical investigation is also exploring exosome therapy for craniofacial neuralgia, though one registered trial (NCT04202783) has been suspended, indicating possible challenges in this application.
Cardiovascular Protection
Preclinical studies have identified cardioprotective mechanisms, particularly involving miR-150-5p found in exosomes derived from human amniotic membrane mesenchymal cells. However, no clinical trials specifically targeting cardiovascular conditions were identified.
Pain Management
One active Phase 1 clinical trial (NCT07587047) is currently recruiting participants to study IV exosome therapy for lower back pain, representing the most advanced clinical application currently under investigation.
Reproductive Health
Experimental models suggest potential for treating intrauterine adhesions using mesenchymal stem cell-derived exosomes for endometrial regeneration, though this remains at the preclinical research stage.
Limitations and Current Status
The clinical evidence for IV exosome therapy is notably thin. Most research consists of preclinical studies using animal models, with very few active human clinical trials. Several registered trials have been suspended, terminated, or have unknown status, suggesting significant challenges in translating preclinical findings to clinical practice.
Important Note: This therapy is largely investigational. Patients should consult with healthcare providers about established treatments for their specific conditions, as exosome therapy is not yet proven safe or effective for routine clinical use.